Symbols / AVDL $21.64 +0.00% Avadel Pharmaceuticals PLC
AVDL Chart
About
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 2.12B |
| Enterprise Value | 2.06B | Income | -278.00K | Sales | 248.52M |
| Book/sh | 1.01 | Cash/sh | 0.94 | Dividend Yield | — |
| Payout | 0.00% | Employees | 188 | IPO | Jun 07, 1996 |
| P/E | inf | Forward P/E | 27.74 | PEG | — |
| P/S | 8.55 | P/B | 21.43 | P/C | — |
| EV/EBITDA | 762.91 | EV/Sales | 8.29 | Quick Ratio | 2.15 |
| Current Ratio | 2.76 | Debt/Eq | 38.05 | LT Debt/Eq | — |
| EPS (ttm) | 0.00 | EPS next Y | 0.78 | EPS Growth | — |
| Revenue Growth | 54.90% | Earnings | 2026-03-02 | ROA | -0.34% |
| ROE | -0.32% | ROIC | — | Gross Margin | 94.91% |
| Oper. Margin | 2.50% | Profit Margin | -0.11% | Shs Outstand | 98.15M |
| Shs Float | 91.56M | Short Float | 2.38% | Short Ratio | 1.60 |
| Short Interest | — | 52W High | 23.57 | 52W Low | 6.38 |
| Beta | — | Avg Volume | 2.18M | Volume | 35.02M |
| Target Price | $20.71 | Recom | Hold | Prev Close | $21.64 |
| Price | $21.64 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$20.71
Mean price target
2. Current target
$21.64
Latest analyst target
3. DCF / Fair value
$0.50
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$21.64
Low
$18.50
High
$23.00
Mean
$20.71
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-20 | main | Wells Fargo | Equal-Weight → Equal-Weight | $23 |
| 2025-11-07 | main | Wells Fargo | Equal-Weight → Equal-Weight | $20 |
| 2025-10-28 | down | UBS | Buy → Neutral | $20 |
| 2025-10-23 | down | Leerink Partners | Outperform → Market Perform | $19 |
| 2025-10-23 | down | HC Wainwright & Co. | Buy → Neutral | $20 |
| 2025-10-22 | down | Jefferies | Buy → Hold | $20 |
| 2025-10-22 | down | Needham | Buy → Hold | — |
| 2025-09-05 | main | HC Wainwright & Co. | Buy → Buy | $36 |
| 2025-09-03 | init | Wells Fargo | — → Equal-Weight | $16 |
| 2025-08-21 | main | UBS | Buy → Buy | $20 |
| 2025-08-08 | main | HC Wainwright & Co. | Buy → Buy | $24 |
| 2025-05-08 | reit | Needham | Buy → Buy | $19 |
| 2025-04-09 | reit | Needham | Buy → Buy | $19 |
| 2025-03-04 | reit | Needham | Buy → Buy | $19 |
| 2025-03-04 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2025-03-03 | reit | Needham | Buy → Buy | $19 |
| 2025-02-11 | init | Deutsche Bank | — → Buy | $12 |
| 2025-01-13 | main | UBS | Buy → Buy | $14 |
| 2025-01-10 | main | Piper Sandler | Overweight → Overweight | $13 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
- AVDL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI Sat, 04 Apr 2026 15
- Avadel (AVDL) Gets 26% Boost on Takeover Bid - Yahoo Finance Sun, 16 Nov 2025 08
- Irish court clears Alkermes buyout; Avadel stock trading ends Feb. 11 - Stock Titan ue, 10 Feb 2026 08
- Assessing Avadel Pharmaceuticals (AVDL) Valuation As Shares Hover Near US$21 After Strong One Year Return - simplywall.st Fri, 13 Feb 2026 08
- Avadel Stock: Mispriced Leader In Once-Nightly Sleep Therapies (NASDAQ:AVDL) - Seeking Alpha ue, 30 Sep 2025 07
- Avadel stock soars after receiving $23 per share acquisition offer - Investing.com Fri, 14 Nov 2025 08
- Analysts Are Split On This 'Very Confusing' $2.1 Billion Buyout - Investor's Business Daily Wed, 22 Oct 2025 07
- Stocks making big premarket moves: WBD, CDTX, AVDL and more - CNBC Fri, 14 Nov 2025 08
- Shareholders back Avadel sale to Alkermes after strong vote - Stock Titan Mon, 12 Jan 2026 08
- Avadel Pharmaceuticals (AVDL): Evaluating Valuation After Recent Share Price Surge - Yahoo Finance Sun, 30 Nov 2025 08
- Avadel climbs as Lundbeck outbids Alkermes in latest bidding war - Seeking Alpha Fri, 14 Nov 2025 08
- A Fresh Look at Avadel Pharmaceuticals (AVDL) Valuation After Share Price Rally - Yahoo Finance Sat, 15 Nov 2025 08
- Avadel (Nasdaq: AVDL) mails proxy, sets Jan. 12 scheme and EGM on Alkermes deal - Stock Titan Wed, 03 Dec 2025 08
- Avadel (NASDAQ: AVDL) and Jazz end litigation; LUMRYZ licensed, royalties through 2036 - Stock Titan Wed, 22 Oct 2025 07
- Rechecking Avadel Pharmaceuticals (AVDL) Valuation After Strong Share Price Momentum - Yahoo Finance ue, 13 Jan 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
169.12
+504.79%
|
27.96
|
0.00
|
0.00
|
| Operating Revenue |
|
169.12
+504.79%
|
27.96
|
0.00
|
0.00
|
| Cost Of Revenue |
|
15.28
+1705.79%
|
0.85
|
0.00
|
0.00
|
| Reconciled Cost Of Revenue |
|
15.28
+1705.79%
|
0.85
|
0.00
|
0.00
|
| Gross Profit |
|
153.84
+467.32%
|
27.12
|
0.00
|
0.00
|
| Operating Expense |
|
196.24
+18.96%
|
164.97
+73.25%
|
95.22
+11.23%
|
85.60
|
| Research And Development |
|
15.20
+14.59%
|
13.26
-35.94%
|
20.70
+21.02%
|
17.10
|
| Selling General And Administration |
|
181.04
+19.34%
|
151.71
+103.59%
|
74.52
+8.79%
|
68.50
|
| Total Expenses |
|
211.52
+27.56%
|
165.81
+74.14%
|
95.22
+11.23%
|
85.60
|
| Operating Income |
|
-42.40
+69.24%
|
-137.85
-44.78%
|
-95.22
-11.23%
|
-85.60
|
| Total Operating Income As Reported |
|
-42.40
+69.24%
|
-137.85
-39.86%
|
-98.56
-15.21%
|
-85.55
|
| EBITDA |
|
-35.57
+76.15%
|
-149.12
-52.79%
|
-97.60
-18.47%
|
-82.39
|
| Normalized EBITDA |
|
-39.72
+70.81%
|
-136.08
-45.20%
|
-93.72
-10.54%
|
-84.78
|
| Reconciled Depreciation |
|
2.68
+51.81%
|
1.77
+18.29%
|
1.49
+83.19%
|
0.81
|
| EBIT |
|
-38.25
+74.65%
|
-150.89
-52.27%
|
-99.10
-19.10%
|
-83.20
|
| Total Unusual Items |
|
4.15
+131.82%
|
-13.04
-236.05%
|
-3.88
-261.98%
|
2.40
|
| Total Unusual Items Excluding Goodwill |
|
4.15
+131.82%
|
-13.04
-236.05%
|
-3.88
-261.98%
|
2.40
|
| Special Income Charges |
|
0.00
+100.00%
|
-13.13
-292.50%
|
-3.35
-6411.32%
|
0.05
|
| Other Special Charges |
|
—
|
13.13
|
—
|
—
|
| Restructuring And Mergern Acquisition |
|
0.00
|
0.00
-100.00%
|
3.35
+6411.32%
|
-0.05
|
| Net Income |
|
-48.83
+69.53%
|
-160.28
-16.59%
|
-137.46
-77.77%
|
-77.33
|
| Pretax Income |
|
-49.08
+69.47%
|
-160.78
-44.27%
|
-111.44
-19.64%
|
-93.14
|
| Net Non Operating Interest Income Expense |
|
-10.83
-9.55%
|
-9.89
+19.90%
|
-12.34
-24.14%
|
-9.94
|
| Interest Expense Non Operating |
|
10.83
+9.55%
|
9.89
-19.90%
|
12.34
+24.14%
|
9.94
|
| Net Interest Income |
|
-10.83
-9.55%
|
-9.89
+19.90%
|
-12.34
-24.14%
|
-9.94
|
| Interest Expense |
|
10.83
+9.55%
|
9.89
-19.90%
|
12.34
+24.14%
|
9.94
|
| Other Income Expense |
|
4.15
+131.82%
|
-13.04
-236.05%
|
-3.88
-261.98%
|
2.40
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
0.22
|
| Gain On Sale Of Security |
|
4.15
+4670.11%
|
0.09
+116.23%
|
-0.54
-122.88%
|
2.34
|
| Gain On Sale Of Business |
|
—
|
—
|
—
|
0.00
|
| Tax Provision |
|
-0.25
+50.70%
|
-0.50
-101.93%
|
26.02
+264.55%
|
-15.82
|
| Tax Rate For Calcs |
|
0.00
+61.52%
|
0.00
-98.52%
|
0.00
+23.67%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.02
+151.39%
|
-0.04
+95.01%
|
-0.82
-300.33%
|
0.41
|
| Net Income Including Noncontrolling Interests |
|
-48.83
+69.53%
|
-160.28
-16.59%
|
-137.46
-77.77%
|
-77.33
|
| Net Income From Continuing Operation Net Minority Interest |
|
-48.83
+69.53%
|
-160.28
-16.59%
|
-137.46
-77.77%
|
-77.33
|
| Net Income From Continuing And Discontinued Operation |
|
-48.83
+69.53%
|
-160.28
-16.59%
|
-137.46
-77.77%
|
-77.33
|
| Net Income Continuous Operations |
|
-48.83
+69.53%
|
-160.28
-16.59%
|
-137.46
-77.77%
|
-77.33
|
| Normalized Income |
|
-52.96
+64.04%
|
-147.27
-9.58%
|
-134.40
-69.44%
|
-79.32
|
| Net Income Common Stockholders |
|
-48.83
+69.53%
|
-160.28
-16.59%
|
-137.46
-77.77%
|
-77.33
|
| Diluted EPS |
|
-0.51
+74.50%
|
-2.00
+12.66%
|
-2.29
-73.48%
|
-1.32
|
| Basic EPS |
|
-0.51
+74.50%
|
-2.00
+12.66%
|
-2.29
-73.48%
|
-1.32
|
| Basic Average Shares |
|
95.14
+18.67%
|
80.17
+33.41%
|
60.09
+2.66%
|
58.53
|
| Diluted Average Shares |
|
95.14
+18.67%
|
80.17
+33.41%
|
60.09
+2.66%
|
58.53
|
| Diluted NI Availto Com Stockholders |
|
-48.83
+69.53%
|
-160.28
-16.59%
|
-137.46
-77.77%
|
-77.33
|
| Amortization |
|
—
|
—
|
—
|
0.00
|
| Amortization Of Intangibles Income Statement |
|
—
|
—
|
—
|
0.00
|
| Depreciation Amortization Depletion Income Statement |
|
—
|
—
|
—
|
0.00
|
| Depreciation And Amortization In Income Statement |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
164.70
|
| Current Assets |
|
134.20
|
| Cash Cash Equivalents And Short Term Investments |
|
105.11
|
| Cash And Cash Equivalents |
|
31.17
|
| Other Short Term Investments |
|
73.94
|
| Receivables |
|
12.10
|
| Accounts Receivable |
|
12.10
|
| Taxes Receivable |
|
1.32
|
| Inventory |
|
10.38
|
| Raw Materials |
|
5.29
|
| Work In Process |
|
2.04
|
| Finished Goods |
|
3.05
|
| Prepaid Assets |
|
4.37
|
| Other Current Assets |
|
2.23
|
| Total Non Current Assets |
|
30.50
|
| Net PPE |
|
13.08
|
| Gross PPE |
|
13.96
|
| Accumulated Depreciation |
|
-0.88
|
| Machinery Furniture Equipment |
|
1.47
|
| Other Properties |
|
12.50
|
| Goodwill And Other Intangible Assets |
|
16.84
|
| Goodwill |
|
16.84
|
| Non Current Accounts Receivable |
|
0.33
|
| Non Current Deferred Assets |
|
—
|
| Non Current Deferred Taxes Assets |
|
—
|
| Other Non Current Assets |
|
0.58
|
| Total Liabilities Net Minority Interest |
|
76.96
|
| Current Liabilities |
|
36.85
|
| Payables And Accrued Expenses |
|
24.12
|
| Payables |
|
12.16
|
| Accounts Payable |
|
11.43
|
| Other Payable |
|
0.73
|
| Current Accrued Expenses |
|
11.96
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
7.49
|
| Current Debt And Capital Lease Obligation |
|
0.93
|
| Current Debt |
|
—
|
| Other Current Borrowings |
|
—
|
| Current Capital Lease Obligation |
|
0.93
|
| Other Current Liabilities |
|
0.26
|
| Total Non Current Liabilities Net Minority Interest |
|
40.10
|
| Long Term Debt And Capital Lease Obligation |
|
1.69
|
| Long Term Debt |
|
—
|
| Long Term Capital Lease Obligation |
|
1.69
|
| Tradeand Other Payables Non Current |
|
5.41
|
| Other Non Current Liabilities |
|
33.01
|
| Stockholders Equity |
|
87.74
|
| Common Stock Equity |
|
87.69
|
| Capital Stock |
|
0.95
|
| Common Stock |
|
0.90
|
| Preferred Stock |
|
0.05
|
| Share Issued |
|
89.83
|
| Ordinary Shares Number |
|
89.83
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
855.45
|
| Retained Earnings |
|
-745.50
|
| Gains Losses Not Affecting Retained Earnings |
|
-23.17
|
| Other Equity Adjustments |
|
-23.17
|
| Total Equity Gross Minority Interest |
|
87.74
|
| Total Capitalization |
|
87.74
|
| Working Capital |
|
97.35
|
| Invested Capital |
|
87.69
|
| Total Debt |
|
2.62
|
| Net Debt |
|
—
|
| Capital Lease Obligations |
|
2.62
|
| Net Tangible Assets |
|
70.90
|
| Tangible Book Value |
|
70.85
|
| Current Provisions |
|
4.04
|
| Interest Payable |
|
0.00
|
| Preferred Stock Equity |
|
0.05
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-46.91
+63.50%
|
-128.51
-82.79%
|
-70.30
+9.06%
|
-77.31
|
| Cash Flow From Continuing Operating Activities |
|
-46.91
+63.50%
|
-128.51
-82.79%
|
-70.30
+9.06%
|
-77.31
|
| Net Income From Continuing Operations |
|
-48.83
+69.53%
|
-160.28
-16.59%
|
-137.46
-77.77%
|
-77.33
|
| Depreciation Amortization Depletion |
|
2.68
+51.81%
|
1.77
+18.29%
|
1.49
+83.19%
|
0.81
|
| Depreciation And Amortization |
|
2.68
+51.81%
|
1.77
+18.29%
|
1.49
+83.19%
|
0.81
|
| Other Non Cash Items |
|
-0.83
-120.40%
|
4.06
-49.86%
|
8.09
+251.45%
|
2.30
|
| Stock Based Compensation |
|
20.39
+28.94%
|
15.81
+125.45%
|
7.01
-20.95%
|
8.87
|
| Deferred Tax |
|
0.00
|
0.00
-100.00%
|
26.02
+266.12%
|
-15.67
|
| Deferred Income Tax |
|
0.00
|
0.00
-100.00%
|
26.02
+266.12%
|
-15.67
|
| Operating Gains Losses |
|
—
|
13.13
|
—
|
—
|
| Change In Working Capital |
|
-20.32
-577.39%
|
-3.00
-112.22%
|
24.54
+564.01%
|
3.69
|
| Change In Receivables |
|
-21.99
-81.72%
|
-12.10
|
0.00
-100.00%
|
2.80
|
| Changes In Account Receivables |
|
-21.99
-81.72%
|
-12.10
|
0.00
|
0.00
|
| Change In Inventory |
|
-9.22
+3.28%
|
-9.53
|
0.00
|
0.00
|
| Change In Prepaid Assets |
|
0.42
+119.30%
|
-2.15
-106.96%
|
30.95
+7150.11%
|
-0.44
|
| Change In Payables And Accrued Expense |
|
12.33
-33.12%
|
18.44
+739.95%
|
-2.88
-156.19%
|
5.13
|
| Change In Accrued Expense |
|
16.42
-2.77%
|
16.89
+7341.41%
|
0.23
-74.64%
|
0.90
|
| Change In Payable |
|
-4.09
-364.92%
|
1.54
+149.71%
|
-3.11
-173.44%
|
4.23
|
| Change In Account Payable |
|
-4.09
-364.92%
|
1.54
+149.71%
|
-3.11
-173.44%
|
4.23
|
| Change In Other Working Capital |
|
-1.85
-178.55%
|
2.35
+166.61%
|
-3.53
+6.73%
|
-3.79
|
| Investing Cash Flow |
|
51.78
+203.37%
|
-50.09
-162.85%
|
79.70
+40.00%
|
56.93
|
| Cash Flow From Continuing Investing Activities |
|
51.78
+203.37%
|
-50.09
-162.85%
|
79.70
+40.00%
|
56.93
|
| Net PPE Purchase And Sale |
|
0.00
|
0.00
+100.00%
|
-0.72
-2653.85%
|
-0.03
|
| Purchase Of PPE |
|
0.00
|
0.00
+100.00%
|
-0.72
-2653.85%
|
-0.03
|
| Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Capital Expenditure |
|
—
|
—
|
-0.72
-2653.85%
|
-0.03
|
| Net Investment Purchase And Sale |
|
51.78
+203.37%
|
-50.09
-162.29%
|
80.41
+98.77%
|
40.45
|
| Purchase Of Investment |
|
-276.00
-16.34%
|
-237.23
-6848.71%
|
-3.41
+94.47%
|
-61.77
|
| Sale Of Investment |
|
327.78
+75.16%
|
187.14
+123.24%
|
83.83
-18.00%
|
102.22
|
| Net Business Purchase And Sale |
|
—
|
0.00
|
0.00
-100.00%
|
16.50
|
| Gain Loss On Sale Of Business |
|
—
|
—
|
—
|
0.00
|
| Financing Cash Flow |
|
15.97
-88.20%
|
135.34
+830.59%
|
14.54
+5429.66%
|
0.26
|
| Cash Flow From Continuing Financing Activities |
|
15.97
-88.20%
|
135.34
+830.59%
|
14.54
+5429.66%
|
0.26
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-38.66
-346.84%
|
-8.65
|
0.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-38.66
-346.84%
|
-8.65
|
0.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-38.66
-346.84%
|
-8.65
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-38.66
-346.84%
|
-8.65
|
0.00
|
| Net Common Stock Issuance |
|
9.25
-93.67%
|
146.06
+476.92%
|
25.32
|
0.00
|
| Proceeds From Stock Option Exercised |
|
6.72
+193.07%
|
2.29
-14.50%
|
2.68
+919.77%
|
0.26
|
| Net Other Financing Charges |
|
—
|
25.64
+633.78%
|
-4.80
|
—
|
| Changes In Cash |
|
20.84
+148.17%
|
-43.27
-280.76%
|
23.94
+218.98%
|
-20.12
|
| Effect Of Exchange Rate Changes |
|
-0.64
-240.44%
|
0.46
+168.52%
|
-0.66
+25.89%
|
-0.90
|
| Beginning Cash Position |
|
31.17
-57.87%
|
73.98
+45.90%
|
50.71
-29.30%
|
71.72
|
| End Cash Position |
|
51.37
+64.82%
|
31.17
-57.87%
|
73.98
+45.90%
|
50.71
|
| Free Cash Flow |
|
-46.91
+63.50%
|
-128.51
-80.95%
|
-71.02
+8.17%
|
-77.34
|
| Interest Paid Supplemental Data |
|
7.18
+36.78%
|
5.25
-45.65%
|
9.66
+49.33%
|
6.47
|
| Income Tax Paid Supplemental Data |
|
—
|
0.00
|
—
|
0.08
|
| Common Stock Issuance |
|
9.25
-93.67%
|
146.06
+476.92%
|
25.32
|
0.00
|
| Issuance Of Capital Stock |
|
9.25
-93.67%
|
146.06
+476.92%
|
25.32
|
0.00
|
| Sale Of Business |
|
—
|
0.00
|
0.00
-100.00%
|
16.50
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|